NVO's Wegovy vs. LLY's Tirzepatide: Who Leads in Heart Risk Reduction?

Novo Nordisk's Wegovy demonstrated a significant advantage over Eli Lilly's tirzepatide in a real-world study, reducing major adverse cardiovascular events by up to 57% in overweight or obese patients with established cardiovascular disease but without diabetes. This data reinforces Wegovy's unique position as the only GLP-1 with proven cardiovascular protection for this specific patient cohort, potentially boosting NVO's sales and strengthening its competitive stance against Lilly's own efforts to expand tirzepatide's cardiovascular indications.

Analysis

Novo Nordisk's real-world STEER study data presents a significant clinical victory for Wegovy, demonstrating a 57% greater reduction in major adverse cardiovascular events compared to Eli Lilly's tirzepatide in adherent patients with obesity and cardiovascular disease but without diabetes. This finding reinforces Wegovy's unique market position as the only GLP-1 therapy with proven cardiovascular protection in this specific patient cohort, potentially strengthening its commercial outlook against fierce competition. However, this positive clinical news is starkly contrasted by bearish financial indicators. Novo Nordisk's stock has underperformed its industry substantially, declining 34.4% year-to-date. This negative momentum is underpinned by deteriorating analyst sentiment, evidenced by downward revisions to 2025 and 2026 earnings estimates over the last 60 days, with the 2026 forecast cut from $4.58 to $4.09 per share. While the company trades at a discounted forward P/E of 14.09 and maintains a superior return on equity of 78.64%, these fundamentals are currently overshadowed by the negative estimate trends and a Zacks Rank #5 (Strong Sell) rating.

Key Decisions for Investors

• Investors should weigh the compelling clinical data from the STEER study, which strengthens Wegovy's long-term competitive moat, against the significant near-term headwinds reflected in the stock's 34.4% year-to-date decline and downward earnings estimate revisions.
• While the stock appears discounted with a forward P/E of 14.09, the sharp deterioration in 2026 earnings estimates and a 'Strong Sell' rating suggest a potential value trap, warranting caution before establishing or adding to long positions.
• Monitor competitive developments closely, particularly Eli Lilly's progress toward a cardiovascular label expansion for tirzepatide by 2025 and data readouts from emerging players like Viking Therapeutics, as these could alter the long-term market dynamics for GLP-1 therapies.